Pfizer Inc. and BioNTech SE said a third dose of their COVID vaccine increased antibodies against the omicron strain by 36-fold in a clinical trial.
The companies plan to file for emergency-use authorization in the U.S. in the coming days based on these results, they said in a statement Thursday. They will also submit the data to other regulators around the world.
In the trial, 140 kids ages 5 to 11 were given a third shot of a 10 microgram dose of the vaccine about six months after their second dose. A month later, antibodies against the original COVID virus were roughly 6 fold higher compared to what they had been one month after the second dose.
